Targeting Angiogenesis for Controlling Neuroblastoma by Roy Choudhury, Subhasree et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2012, Article ID 782020, 15 pages
doi:10.1155/2012/782020
Review Article
Targeting AngiogenesisforControllingNeuroblastoma
SubhasreeRoy Choudhury,1 SurajitKarmakar,1 Naren L. Banik,2 andSwapanK. Ray1
1Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine,
Columbia, SC 29209, USA
2Department of Neurosciences, Medical University of South Carolina, Charleston, SC 29425, USA
Correspondence should be addressed to Swapan K. Ray, swapan.ray@uscmed.sc.edu
Received 6 May 2011; Accepted 3 June 2011
Academic Editor: Arkadiusz Dudek
Copyright © 2012 Subhasree Roy Choudhury et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Neuroblastoma, a progressive solid tumor in childhood, continues to be a clinical challenge. It is highly vascular, heterogeneous,
and extracranial tumor that originates from neural crest. Angiogenesis, genetic abnormalities, and oncogene ampliﬁcation are
mainly responsible for malignant phenotype of this tumor. Survivability of malignant neuroblastoma patients remains poor
despite the use of traditional therapeutic strategies. Angiogenesis is a very common and necessary pre-requisite for tumor
progression and metastasis. Angiogenesis is also a major factor in making malignant neuroblastoma. Thus, prevention of
angiogenesis can be a highly signiﬁcant strategy in the treatment of malignant neuroblastoma. Here, we summarize our current
understanding of angiogenesis in malignant neuroblstoma and describe the use of experimental anti-angiogenic agents either
alone or in combination therapy. This review will clearly indicate the importance of angiogenesis in the pathogenesis of malignant
neuroblastoma, its prevention as a promising therapy in preclinical models of malignant neuroblastoma, and prospective clinical
trials.
1.Introduction
Neuroblastoma is the most common, extracranial, and het-
erogeneous solid tumor in children, and it accounts for
approximately 15% of pediatric cancer deaths with an
estimated incidence of 1 per 7000 births in the USA [1,
2]. This embryonal cancer of postganglionic sympathetic
nervous system arises from adrenal gland and less frequently
metastasizes in other places such as chest, neck, lymph
nodes, pelvis, liver, and bone. The prognosis is variable and
depends on several factors. Neuroblastoma is characterized
by its intriguing clinical behaviors that include spontaneous
diﬀerentiation and regression, maturation into benign gan-
glioneuroma, and deadly metastatic tumor. This childhood
neoplasm is staged clinically according to the Interna-
tional Neuroblastoma Staging System (INSS) (Figure 1). The
genetic features of neuroblastoma include N-Myc oncogene
ampliﬁcation or allelic loss, near triploid karyotype, deletion
of short arm of chromosome 1, and high expression of
neurotrophin receptors (TrkA and TrkB), all of which
are associated with malignant transformation and pro-
gression of this disease. Multimodal treatment approaches
including myeloablative chemotherapy, radionuclide ther-
apy, immunotherapy, and apoptosis-inducing therapy are
evaluated as traditional therapeutic strategies for controlling
the malignant growth of the tumors. Despite aggressive
conventional treatments and diagnosis techniques in neu-
rosurgery, the survival rate for patients with neuroblastoma
remains poor because the majority of children older than
1 year of age with advanced stage neuroblastoma die from
progressive disease and only 40% of children over 4 years
old with neuroblastoma survive for 5 years, emphasizing
the urgent need for the development of innovative thera-
peutic strategies for treatment of malignant neuroblastoma.
Malignant neuroblastoma is a highly vascularized solid
tumor that requires access to blood vessels for growth,
invasion, and metastasis [3]. Emerging treatments with the
delivery of antiangiogenic molecules can thereby hinder
neovascularization and arrest the spread of this pediatric
tumor. Novel therapeutic approaches with the angiogenic2 Journal of Oncology
Stage 1
Stage 2A
Stage 2B
Unresectable tumor inﬁltrating across the midline, with or without
regional lymph node involvement, unilateral tumor with contralateral
regional lymph node, and midline tumor with bilateral extended
lymph node involvement.
Stage 3
Spread of tumor to distant lymph nodes, skin, bone, bone marrow,
and liver or other organs.
Stage 4S
Stage 4
Localized tumor conﬁned to the area of origin, completely removed
during surgery, and identiﬁable ipsilateral and contralateral lymph
nodes negative microscopically.
Localized primary tumor, as deﬁned for stage 1, 2A, or 2B, with
metastases limited to skin, liver, and bone marrow in children
younger than 1 year. Presence of elevated serum ferritin levels and
E-rosette inhibitory factor distinguish stage 4 neuroblastoma from
stage 4S.
Localized tumor with incomplete gross excision, identiﬁable
ipsilateral and contralateral, and nonadherent lymph nodes negative
for tumor microscopy.
Unilateral tumor with complete or incomplete gross excision, with
positive ipsilateral non-adherent regional lymph nodes, identiﬁable
enlarged contralateral lymph nodes negative microscopically.
Figure 1: Staging system for neuroblastoma according to the INSS.
inhibitors are expected to improve patient survivability by
reducing morbidity, mortality, and drug-related toxicity.
2. AngiogenesisinHumanNeuroblastoma
Angiogenesis is a process of development of intrinsic
vascular network, and it is a prerequisite for progression
and metastatic spread of solid tumors like neuroblastoma
where new capillaries sprout from preexisting vessels and
the transition from avascular to vascular phase occurs via
neovascularization. Tumor angiogenesis is characterized by
cascade of events involving mainly dissolution of vascular
basalmembrane,increasedvascularpermeability,anddegra-
dation of extracellular matrix resulting in endothelial cell
migration, invasion, proliferation, and tube formation [4–
7]. Finally, the recruitment of perivascular supporting cells
suchaspericytes,subsequentinhibitionofendothelialprolif-
eration, basement membrane reconstitution, and structural
reorganization into a functional complex formation stabilize
the microvasculature.
Angiogenesis is mediated by multiple regulatory factors
such as growth factors, adhesion molecules, and matrix
degrading enzymes. Activation of endothelial cell prolif-
eration and migration are mainly regulated by receptor
tyrosine kinase ligands such as vascular endothelial growth
factor (VEGF), ﬁbroblast growth factor-2 (FGF-2), platelet
derived growth factor (PDGF), epidermal growth factor
(EGF), transforming growth factor-alpha (TGF-α), and
angiopoietins (Ang-1 and Ang-2). The naturally occurring
endogenous angiogenesis inhibitors that aﬀect neurob-
lastoma growth in vivo includes angiostatin, endostatin,
tumstatin, canstatin, tissue inhibitors of matrix metallo-
proteinases (MMP), and so forth. An angiogenic switch
actually maintains the balance between angiogenic activators
and inhibitors and maintains the endothelial cells in an
angiogenic or quiescent stage. Malignant growth of human
neuroblastoma is highly dependent on angiogenesis. There-
fore, anti-angiogenic strategies can be eﬀective in inhibiting
tumor cell dissemination and metastasis in highly vascular
neuroblastoma [3–7].
3. Angiogenesis StimulatoryFactorsin
Human Neuroblastoma
3.1. Angiogenic Growth Factors and Their Implications
3.1.1. VEGF and VEGFR Family. VEGF (46kDa) is an
endothelialspeciﬁcmitogenthatplaysacrucialroleinpatho-
genesis and neovascularization of neuroblastoma. VEGF sig-
naling plays a regulatory role in neuroblastoma angiogenesis
via a paracrine mechanism through two speciﬁc tyrosine
kinase VEGF receptors: VEGFR-1 (or Flt-1) and VEGFR-2
(or KDR) at the surface of the endothelial cells. The most
potent angiogenic factor to promote endothelial cell prolif-
eration is VEGF-A. Encoded by a single gene, VEGF-A has
severalisoformssuchasVEGF-A 121,VEGF-A 165,VEGF-A 189,
and VEGF-A206, which are generated by alternative exon
splicing. The other members of the VEGF family include
VEGF-B, VEGF-C, VEGF-D, and VEGF-E [8, 9]. VEGFR-
2 is the major mediator of VEGF-induced endothelial cell
proliferation, migration, and survival, and it acts as a potentJournal of Oncology 3
microvascular permeability enhancer of VEGF. VEGFR-
3/Flt-4 is a member of the same tyrosine kinase receptors
of VEGF-C and VEGF-D. Another coreceptor known as
neuropilin (NP) also modulates receptor ligand interactions
of the VEGF family. NP-1 enhances the VEGF-A165 binding
withVEGFR-2 whereasNP-2 actsasa functionalreceptorfor
VEGF-A145 and VEGF-A165. VEGF is expressed and secreted
by majority of neuroblastoma cell lines and primary tumors
that contribute to the growth of endothelial cells in vitro
and angiogenesis in vivo leading to poor prognosis in high-
risk neuroblastoma [10]. VEGF-A165 mRNA expression is
upregulated in stage III neuroblastoma [11]. The presence
of VEGF, VEGFR-1, and VEGFR-2 mRNA expression is
evident in neuroblastoma surgical specimens and cell lines
by reverse transcriptase-polymerase chain reaction (RT-
PCR), but neuroblastoma SK-N-BE cell line expresses only
the mRNA of VEGFRs [12]. Hypoxia upregulates VEGF
expression and in conjugation with Flt-1 plays a pivotal
role in VEGF-mediated autocrine signaling of tumor growth
and angiogenesis in neuroblastoma cell line. A hypoxia-
driven VEGF/Flt-1 autocrine loop acts together with hypoxia
inducible factor-1 alpha (HIF-1α) through a mitogen-
activated protein kinase and extracellular signal-regulated
kinase-1/2-mediated pathway in neuroblastoma SK-N-BE2
cell line resulting in tumor cell survivability, multiple drug
resistance, and neuroblastoma vascularity [13]. Neuroblas-
toma cells utilize VEGF both as a stimulator of angiogenesis
and an inhibitor of apoptosis through upregulation of Bcl-
2 expression [14]. Treatment of neuroblastoma in both
in vitro and in vivo models with anti-VEGF agent results
in decrease in tumor vascularity. In both neuroblastoma
cell line and in vivo models, treatment with bortezomib,
a proteasome inhibitor, showed anti-tumor activity with
markeddecreaseinintratumoralvesselcountsandreduction
in VEGF expression suggesting diversiﬁed role of VEGF
in progression of advanced stage neuroblastoma [15, 16].
Theanti-VEGFantibodybevacizumabmarkedlyreducedthe
growth rate of three malignant neuroblastoma SK-N-AS,
IMR-32, and SH-SY5Y xenografts in immunodeﬁcient mice
[17]. ZD6474, a dual tyrosine kinase inhibitor of VEGFR-
2 and EGFR, inhibited the phosphorylation of receptor
tyrosine kinase in neuroblastoma cells leading to an increase
in endothelial cell apoptosis and showed signiﬁcant anti-
tumor activity in seven neuroblastoma cell lines (SK-N-
SH, SK-N-SH, SK-NAS, NGP, CHP-134, SH-SY5Y, and SH-
EP) [18]. Though VEGF is indispensable for neuroblastoma
angiogenesis, treatment of neuroblastoma xenograft model
with anti-VEGF antibody shows decrease in vascularity and
only partial regression of tumor, suggesting that VEGF
blockade is not suﬃcient to prevent neuroblastoma angio-
genesis or apoptosis and multiple angiogenic factors are
needed for progression of neuroblastoma [19]. High levels
of expression of VEGF-A121,V E G F - A 165, VEGF-B, VEGF-C,
FGF-2, Ang-2, TGF-α, and PDGF-A have been documented
in an analysis of 22 neuroblastoma cell lines and 37 tumor
samples suggesting that multiple angiogenic growth factors
interplay in the regulation of neovascularisation in advanced
stage neuroblastoma [20]. Expression of mRNAs in 24
neuroblastoma cell lines and 40 tumor samples using RT-
PCR suggests that expression of c-Kit, PDGFR-β, and Flt-3
mRNA is associated with neuroblastoma in patients under 1
year,whilethelossofexpressionofthesekinasesisassociated
with N-Myc ampliﬁcation in patients over 1 year of age with
advanced stage of neuroblastoma [21].
3.1.2. PDGF and PDGFR Family. PDGF and their cognate
receptor tyrosine kinases have potent implication in mod-
ulating endothelial cell proliferation and angiogenesis in
solid tumors. Neuroblastoma cell lines also express dimeric
isoforms of PDGF: PDGF-AA and PDGF-BB and their
functional receptors PDGFR-α and PDGFR-β,r e s p e c t i v e l y .
PDGF has trophic eﬀects on dopaminergic neurons in vitro.
NB41, a mouse neuroblastoma cell line produces PDGF-AA,
PDGF-BB and PDGFR-β, responding to PDGF-BB but
not to PDGF-AA. Introduction of an antisense PDGFR-β
RNA in NB41 cells completely suppressed neurite extension
and cell growth indicating proliferative activity of PDGF
in tumors [22]. Treatment of 7 neuroblastoma cell lines
with imatinib mesylate displayed concentration-dependent
decreases in cell viability and induction of apoptosis due to
suppressionofc-KitandPDGFRphosphorylation,leadingto
inhibition of growth of neuroblastoma [10]. Treatment of 3
neuroblastoma cell lines such as SK-N-AS, IMR-32, and SH-
SY5Y with SU11657, which is a multiple inhibitor targeting
PDGFR, VEGFR, and c-Kit, reduced their expression and
tumor angiogenesis by 63–96% also signifying the crucial
roles of these angiogenic ligands and their receptors in
t u m o rc e l lp r o l i f e r a t i o na n ds u r v i v a l[ 23]. PDGF mainly
inducesitsactivitythroughRasactivationfollowedbyMAPK
mediated action. Treatment of neuroblastoma SH-SY5Y
cell line with somatostatin causes anti-proliferative eﬀect
by inhibition of PDGF-induced PDGFR phosphorylation
followed by Ras inactivation providing multiple regulatory
role of PDGF in cell proliferation and angiogenesis in high
risk neuroblastoma [24].
3.1.3. Stem Cell Factor and c-Kit Receptor Family. Produced
by marrow stromal cells, stem cell factor (SCF) is a gly-
coprotein hemopoietin growth factor that acts by binding
to its speciﬁc surface protein receptor encoded by the c-Kit
proto-oncogene.SCFandc-KitmRNAsareexpressedinneu-
roblastoma cell lines and tumors, and they regulate tumor
growth, survivability, and angiogenesis [25]. Neuroblastoma
cells treated with an antibody to c-Kit augment apoptosis
[26]. Both SCF and c-Kit are preferentially expressed in N-
Myc ampliﬁed neuroblastoma tumors, and their signaling
is active in promoting neuroblastoma cell proliferation that
can be selectively inhibited by treatment with STI-571,
a tyrosine kinase inhibitor [27]. Retinoic acid treatment
has been shown to induce neuronal diﬀerentiation as well
as enhanced SCF production in neuroblastoma cell lines
[28]. Anti-c-Kit administration in 5 neuroblastoma cell lines
IMR-5, SK-N-SH, SK-N-BE, AF8, and SJ-N-KP and the
neuroepithelioma (NE) line CHP-100 showed signiﬁcant
decrease in cell viability due to induction of apoptosis
suggesting that SCF is produced by some neuroblastoma4 Journal of Oncology
cell lines via an autocrine loop to protect them from apop-
tosis and stimulate neuroblastoma growth and metastasis
[29].
3.1.4. Flt-3 and Receptor Family. Flt-3 is a transmembrane
glycoprotein receptor structurally related to macrophage
colony stimulating factor receptor-1 (CSF-1) and c-Kit, and
it is expressed on several cell types including neuroblastoma
cells. Flt-3 ligand (FL) is a cytokine that promotes the
survival, proliferation, and diﬀerentiation of hematopoietic
progenitors in synergy with other growth factors such as
SCF, IL-3, IL-6, IL-12, and GM-CSF. The levels of expression
of Flt-3 and FL in 12 tumor cell lines from neuroectoder-
mal tumor (NET), Ewing’s sarcoma (ES), and peripheral
neuroectodermal tumor (PNET) and in 38 biopsies were
analyzed [26]. RT-PCR and ﬂow cytometry conﬁrmed the
presence of membrane and cytoplasmic Flt-3 and membrane
FL in all these lines. FL shows a signiﬁcant proliferating and
anti-apoptotic activity in neuroblastoma and neuroepithe-
lioma lines suggesting that Flt-3 and its ligand are expressed
in neural crest-derived tumors and promote survival and
proliferation of their cell lines [26].
3.1.5. MMP Expression in Human Neuroblastoma. In ad-
vanced stages of neuroblastoma, tumor cell secrets MMP
favoring degradation of extracellular matrix and enhanc-
ing tumor dissemination. The family of MMPs includes
72kDa MMP-2 (or gelatinase A) and 92kDa MMP-9 (or
gelatinase B) that are collagenases. MMP-2 and MMP-
9 facilitate invasion and metastasis, and they degrade
important constituents of the interstitial stroma and suben-
dothelial basement membrane type IV, V, VII, and X col-
lagens and ﬁbronectin [14]. Immunohistochemical anal-
ysis of the expression patterns of MMP-2, MMP-9, and
their speciﬁc inhibitor, namely, tissue inhibitor of matrix
metalloproteinase-2 (TIMP-2) in 31 neuroblastoma patients
revealed that increased expression of MMP-2 but not that
of MMP-9 and decreased expression of TIMP-2 in stromal
tissues of neuroblastoma had signiﬁcant association with
progression of advanced stage disease [30]. Stromal MMP-
9 regulates the vascular architecture in neuroblastoma by
promoting pericyte recruitment. Prinomastat, a synthetic
inhibitor of MMPs, shows inhibition of tumor cell prolif-
eration in human neuroblastoma SK-N-BE2 orthotopically
xenotransplanted tumors in immunodeﬁcient mice and pro-
longed survivability, suggesting that advanced stages of neu-
roblastoma show increased expression of both MMP-2 and
MMP-9 [31]. PEGylated SN38 (EZN-2208), a novel topoi-
somerase I inhibitor, showed promising anti-neuroblastoma
eﬃcacy through increasing apoptosis and reducing expres-
sion of VEGF, MMP-2, and MMP-9 in preclinical in vitro
and in vivo models of human neuroblastoma [32]. MMP-2
remains in an inactive form in tumor cell lines and tumor
tissues in the absence of expression of a membrane-type
1-MMP (MT1-MMP), which converts pro-MMP-2 to its
activate form. MMP-9 is not expressed in neuroblastoma cell
lines, but it is present in both inactive and active forms in
tumor tissues [33]. Overexpression of MT1-MMP is highly
associated with the advanced stage high-risk neuroblas-
toma. Increased expression of both MMP-2 and MMP-9 is
also evident from studies in two neuroblastoma cell lines
(LAN-5 and GL-LI-N) and immunohistochemical analysis
of tissue biopsies of human neuroblastoma indicating that
expression of these MMPs is correlated with angiogenesis
in advanced stages [14]. MMPs have a role in retinoic
acid-induced diﬀerentiation in neuroblastoma cell lines.
For example, retinoic acid treatment for 24h transiently
increased invasion and expression of MMP-9 in SH-SY5Y
andLAN-5cellsandMMP-2inSMS-KCNRcells.MMPinhi-
bition prevented retinoic acid-induced neurite formation
indicating a regulatory role of MMP in diﬀerentiation [34].
Human neuroblastoma tumors xenotransplanted in MMP-9
(+/+) and MMP-9 (−/−) mice showed that bone marrow-
derived MMP-9 regulates the recruitment of leukocytes and
endothelial cells along with pericytes from bone marrow
into tumor stoma leading to neovascularization and tumor
progression [35]. N-Myc and Bcl-2 co-expression induces
MMP-2 secretion and activation leading to tumorigenic
phenotype in human neuroblastoma cells [36].
3.1.6. Association of N-Myc Ampliﬁcation with Human Neu-
roblastoma. N-Myc,aproto-oncogenenormallyexpressedin
thedevelopingnervoussystem,isfrequentlyoverexpressedin
high-risk neuroblastoma manifesting increased vasculature
and poor prognosis. Ampliﬁed N-Myc down regulates both
the production and activity of angiogenesis inhibitors and
alsoprovokestumormalignancy[37].N-MyccontainsanN-
terminaltransactivationdomain(Mycbox)andaC-terminal
basic helix-loop-helix/leucine zipper (bHLH-LZ) motif. The
bHLH-LZ region is responsible for both DNA binding and
interactions with other bHLH-LZ proteins (Max and Mad).
N-Myc is normally located on the distal short arm of
chromosome 2(2p24), butincellswithN-Mycampliﬁcation
it also maps to the double minute chromatin bodies (DM) or
homogenously staining regions. Genetic material from chro-
mosome 2p24 is ampliﬁed to form an extrachromosomal
circularelementor is transposed tothe DM withretention of
the normal copies of N-Myc at 2p24. Ampliﬁcation of the N-
Mycoccursin20%to25%ofneuroblastomasandisamarker
of aggressive tumor phenotype [38].
Aftergenomicampliﬁcation,N-Mycactsastranscription
activator by heterodimerization with Max, a ubiquitously
expressed nuclear protein lacking N-terminal transactivating
domain. Interaction of the N-Myc/Max complex with the
promoter region of target genes through the DNA sequence
E-box motif (CACGTG) leads to progression of the cell cycle
through the G1 phase ensuing increased transcription of
severalgeneslikeODC ,MCM7,andMRPI.Inthe absenceof
N-Myc, other nuclear proteins Mad and Mxi1 competitively
bind with Max and act as transcriptional repressor protein
complex to inhibit transcription (Figure 2). Treatment of
the N-Myc-ampliﬁed neuroblastoma cells with combination
of IFN-γ and retinoic acid down regulates N-Myc expres-
sion through increased protein turnover, upregulates Mad1
mRNA and protein, and reduces N-Myc/Max heterodimer-
ization, and predominates Mad1/Max network resulting
in repression of the N-Myc target genes and potentiatingJournal of Oncology 5
N-Myc
Max
CACGTG
Transcriptional
activation
Production of growth
promoting genes
RA +IFN-γ Max Mad Mxi1
Max Max Max
Transcriptional
regression
Ampliﬁed
N-Myc
Activin A
Angiogenesis
PI3K/Akt
VEGF
Trisomy 17q 1p LOH
Ampliﬁcation of 2p22, 2p13,
MDM2 12q13, MYCL 1p32,
4p, 6p, 7p, 11q, 18q
Neuroblastoma tumorigenesis
Mechanism of N-Myc interactions
Figure 2: Schematic presentation of molecular changes associated with N-Myc ampliﬁcation in neuroblastoma. Ampliﬁed N-Myc after het-
erodimerization with Max augments synthesis of several genes and through PI3K/Akt-mediated pathway regulates VEGF signaling resulting
in neuroblastoma tumorigenesis.
diﬀerentiation and growth inhibition in neuroblastoma cells
[39]( Figure 2).
Overexpression of N-Myc down regulates the production
of the anti-angiogenic factor activin A (Figure 2). Increased
activin A expression inhibits neuroblastoma growth and
angiogenesis in a neuroblastoma xenograft model, shows
anti-proliferative activity, decreases colony formation of
human neuroblastoma cell lines with ampliﬁed N-Myc,
and induces diﬀerentiation. Ampliﬁed N-Myc through its
interaction with the activin A promoter suppresses activin
A synthesis resulting in enhanced vascularization to allow
neuroblastoma progression [37].
Other genetic changes associated with N-Myc ampliﬁca-
tion in high-risk neuroblastoma are loss of heterozygosity
on chromosome 1p and ampliﬁcation of DNA on 2p22,
2p13, the MDM2 gene on 12q13, and the MYCL gene
on 1p32. Comparative genomic hybridization reveals that
ampliﬁcations of 4p, 6p, 7q, 11q, and 18q concurrently
with N-Myc ampliﬁcation have occurrence in advanced
stage neuroblastoma. Allelotyping and comparative genomic
hybridization studies indicate that trisomy for the long arm
of chromosome 17 (17q) along with ampliﬁed N-Myc is
indicative marker of aggressive neuroblastoma. Deletion of
11q is a predictive pointer in clinically high-risk neuroblas-
toma patients without N-Myc ampliﬁcation [38]( Figure 2).
N-Myc-ampliﬁed neuroblastoma cell lines either do not
express CD44 or express a non-functional receptor. Absence
of functional CD44 hyaluronan receptor on human N-
Myc-ampliﬁed neuroblastoma cells predicts risk of disease
progression and dissemination [40].
N-Myc plays an important role in the phosphati-
dylinositol-3-kinase- (PI3K-) mediated VEGF regulation
in neuroblastoma cells as evident from the study where
inhibition of N-Myc expression by siRNA transfection
signiﬁcantly blocks VEGF secretion [41]. Targeted inhibi-
tion of N-Myc by peptide nucleic acid (PNA) in human
neuroblastoma N-Myc-ampliﬁed (GI-LI-N) and N-Myc-
unampliﬁed (GI-CA-N) cells showed cell cycle inhibition
with induction of neuronal diﬀerentiation and apoptosis
in N-Myc ampliﬁed cells and caused signiﬁcant reduction
in cell viability with N-Myc translation inhibition, accu-
mulation of cells in G1, and induction of diﬀerentiation
and apoptosis [42]. N-Myc silencing induces diﬀerentiation
and apoptosis in human neuroblastoma cells. Also, siRNA
directedtoN-Mycmayprovideanoveltherapeuticapproach
for an eﬀective treatment of aggressive neuroblastomas
[43].
3.1.7. Neurotrophin Signaling Pathways in Human Neuroblas-
toma. Malignant transformation of sympathetic neuroblasts
to neuroblastoma cells is regulated by neurotrophin receptor
pathways. The tropomyosin related kinase (Trk) family
consists of three receptor tyrosine kinases (TrkA, TrkB, and
TrkC) each of which can be activated by one or more of
the 4 neurotrophins such as nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF), neurotrophin 3
(NT3), and neurotrophin 4 (NT4). Neurotrophins through
intracellular signal transduction pathways mediate diversi-
ﬁed biological activities such as cell survival, proliferation,
and diﬀerentiation in normal and neoplastic neuronal cells.6 Journal of Oncology
High expression of TrkA is present in neuroblastomas with
favorable prognosis correlating with patient survival and
absence of N-Myc ampliﬁcation. Binding of transmembrane
homodimer receptor TrkA to a homodimer of NGF leads
to autophosphorylation of the receptor, docking of signal-
ing proteins, signal transduction, and induction of gene
transcription. TrkA through direct interaction with proteins
SHC, PLCγ1, SH2B, IAPs, and Ras/MAPK signaling pathway
regulates survival and diﬀerentiation and via activation of
PI3K/Akt pathway mediates an alternative survival signaling
pathway. TrkB is mainly expressed on unfavorable, aggressive
neuroblastomas, responsible for both enhanced angiogenesis
and drug resistance and strongly associated with N-Myc
ampliﬁed tumors. Biological eﬀects of TrkA and TrkB
expression on neuroblastoma angiogenesis were examined
in human neuroblastoma SH-SY5Y cell line and its TrkA
and TrkB transfectants. TrkA expression inhibits tumor
growth and down regulates the angiogenic factors VEGF
and FGF-2 in SH-SY5Y cells whereas TrkB transfectants
and parental SH-SY5Y cells induced endothelial cell pro-
liferation and migration [44]. TrkA expression resulted in
severely impaired tumorigenicity and invasiveness in SH-
SY5Y xenografted mice and was associated with reduced
angiogenic factor expression and vascularization of tumors
[44]. NT expression pattern and mutational events leading
to tumorigenesis divided neuroblastomas in distinct three
types [38]. The ﬁrst type is characterized by TrkA expressing
tumors having mitotic dysfunction leading to near triploid
(3N) karyotype. They can diﬀerentiate in response to
NGF or undergo apoptosis in absence of NGF. Second
type is characterized by TrkB expressing tumors having
near diploid (2N) or tetraploid karyotype with genomic
instability(gainofdistal17qmaterial,lossof11qand/or14q
material with 17q gain, and without 1p deletion and N-Myc
ampliﬁcation)andchromosomalstructurealterations.Third
t y p ei sc h a r a c t e r i z e db yt u m o r sw i t h1 pl o s sw i t hN - M y c
ampliﬁcation [38]. Expression of diﬀerent members of Trk
family thus plays a key role in heterogenous clinical outcome
of neuroblastoma.
3.1.8. Expression of Vascular Integrins Associated with Human
Neuroblastoma. Angiogenic neovascularization is also inﬂu-
enced by selective expression of adhesion receptor integrins.
Cell adhesion to the extracellular matrix is mediated by
integrins, which are heterodimeric transmembrane proteins
comprising of a diverse family with over 15α and 8β
subunits. Integrins αvβ3 and αvβ5 are expressed in high-
risk neuroblastoma [45]. The binding of the integrin αvβ3
to its receptor provides a signal that causes reduction in
p53, p21Waf1, and Bax expression and increase in Bcl-2
expression implicating survival of endothelial cells [46].
Expression of the integrins αvβ3 and αvβ5 by microvascular
endothelium was demonstrated by immunohistochemical
analysis [45]. The integrin αvβ3 was expressed by 61% of
microvessels in high-risk neuroblastomas (stage IV and N-
Myc-ampliﬁed stage III) and 18% of microvessels in low-
risk tumors (stages I and II and non-N-Myc ampliﬁed
stage III). The integrin αvβ5 was produced by 60% of
microvessels in stage IV tumors suggesting their association
with neuroblastoma aggressiveness [45]. In vivo echographic
evidence of tumoral vascularization and microenvironment
interactions in metastatic orthotopic human neuroblastoma
xenografts showed highly angiogenic integrin αvβ3 marker
indicating neovascularization to promote the role of cell
adhesion molecules [47].
3.1.9. Osteopontin in Neuroblastoma. Osteopontin (OPN) is
a multifunctional phosphoprotein secreted by multiple cell
types including osteoclasts, lymphocytes, and macrophages,
and OPN is expressed in various tumor cells to act as
a potent angiogenic factor contributing to tumor growth.
OPN through its interaction with αv integrins regulates
both cell attachment and cell signaling. OPN in association
with VEGF stimulates endothelial cell migration [48]. OPN
playsanimportantroleinincreasingtumorigenicitythrough
the enhancement of angiogenesis in vivo. Culture medium
with murine neuroblastoma C1300 cells transfected with
OPN gene signiﬁcantly stimulates human umbilical vein
endothelial cell migration and induces neovascularization
in mice resulting in signiﬁcant increase in tumor growth
[49]. Presence of FGF-2 stimulates OPN upregulation in
endothelial cells resulting in OPN-mediated recruitment
of pro-angiogenic monocytes, induction of expression of
the angiogenic cytokines TNF-α and IL-8 to contribute to
ampliﬁcation of FGF-2-induced neovascularization during
inﬂammation, wound healing, and tumor growth [50].
3.1.10. Role of HGF/c-Met Signaling in Neuroblastoma. Both
N-Myc ampliﬁcation and elevated expression of the neu-
rotrophin receptor TrkB are correlated with the malignant
phenotype of neuroblastoma. The TrkB-mediated invasive-
ness is associated with upregulation of hepatocyte growth
factor (HGF) and its receptor c-Met [51]. HGF and c-
Met are heterodimers composed of a α-chain subunit and
a β-chain subunit linked by a disulﬁde bond. Mature
HGF is a heterodimer composed of a α-chain (69kDa),
which contains an N-terminal hairpin domain and four
kringle domains, and a β-chain (34kDa) having serine-
protease-like domain. Mature c-Met is comprised of a
glycosylated α-subunit (50kDa) and a transmembrane β-
subunit (145kDa). The extracellular region of mature c-Met
containsaSemadomain,whichisacysteine-richMet-related
sequence (MRS) domain, and four immunoglobulin-like
structure domain. The intracellular region is composed of a
juxtamembrane domain, which is a tyrosine kinase domain
(Tyr 1234 and Tyr 1235) that regulates kinase activity of c-
Met,andaC-terminalregulatorytail(Tyr1349andTyr1356)
that is responsible for c-Met-regulated signal transduction
pathway [52].
After binding of HGF to c-Met or other receptor tyrosine
kinases, the HGF/c-Met signaling is initiated. Dimerization
of c-Met causes transphosphorylation of tyrosines (Tyr 1234
and Tyr 1235) in the kinase domain followed by additional
phosphorylation of other tyrosines (Tyr 1349 and Tyr 1356)
in the C-terminal regulatory tail. c-Met transmits HGF
signaling in cells via various downstream eﬀectors such as
Src/FAK, which regulates cell migration and adhesion. The
other HGF/c-Met-associated eﬀectors such as p120/STAT3Journal of Oncology 7
pathway augments neovasculature of cells whereas the
PI3K/Akt and Ras/MEK pathways are responsible for cell
proliferation and cell survival [52]. Thus, HGF mediates
these multiple signaling cascades in endothelial cells directly
or via involvement of VEGF and its receptor to promote
angiogenesis. The important downstream eﬀector of HGF/c-
Met signaling that promotes neuroblastoma progression is
STAT3 [53], one of the well-recognized signal transduction
pathwaysinvolved in angiogenesis andothersteps in cancers.
4. Anti-Angiogenic Therapy for
Controlling Neuroblastoma
4.1. Single Anti-Angiogenic Agent Therapy for
Controlling Neuroblastoma
4.1.1. Inhibition of VEGF and VEGFR. VEGF is a critical
mitogen regulating growth, neovascularization, and migra-
tionofendothelialcellsandisassociatedwithpoorprognosis
in neuroblastoma. VEGF and its receptors are expressed in
human neuroblastoma tumors and cell lines. VEGF acts
primarilybybindingtooneofitscognatereceptors(VEGFR-
1, VEGFR-2, and VEGFR-3) on endothelial cells, leading
to autophosphorylation of tyrosine residues followed by
subsequent activation of multiple intracellular signal trans-
ductionpathwayssuchastheMAPKandPI3K/Aktpathways.
Several experimental therapeutic strategies including VEGF
inhibitors, antibodies directed against VEGF or against its
receptors, soluble truncated receptors, introduction of anti-
sense VEGF RNA, development of dominant-negative VEGF
mutants and agents interfering directly with VEGF signal
transduction have been emerged to target the interaction of
VEGF with its receptors and thereby to suppress growth of
neuroblastoma [54].
AZD2171, a selective inhibitor of the VEGF receptor
family, displayed inhibition of tumor growth in neurob-
lastoma xenografts showing a promising anti-angiogenic
treatment strategy for solid tumors [55]. Treatments with
SB202190 (the p38 MAPK inhibitor) enhanced VEGF-
mediated protection of the serum-deprived neuroblastoma
SK-N-SH cells by reducing caspase-3 and caspase-7 activities
and increasing the phosphorylation of the extracellular
signal-regulated kinase 1/2 (ERK1/2) and Akt signaling
pathway through activation of VEGFR-2. A blockade of
VEGFR-2 signaling with the selective inhibitor SU1498 or
gene silencing with VEGFR-2 siRNA in SB202190 treated
cells hindered this prosurvival response and highly induced
activation of caspase-3 and caspase-7, indicating that p38
MAPK exerts a negative eﬀect on VEGF-mediated signaling
through VEGFR-2 in serum-starved neuroblastoma cells
[56]. Combinatorial treatment with vinblastine, a mono-
clonal antibody (DC101) targeting VEGFR-2 and rapamycin
(mTOR inhibitor) in both neuroblastoma cells and ortho-
topic xenografted mice showed signiﬁcant inhibition of
tumor growth, angiogenesis, and reduction in microvessel
formation suggesting that this combination may be relevant
to design new curative strategies against neuroblastoma
[57]. Argatroban (a derivative of arginine and a potent
anti-coagulant and anti-thrombin agent) serves as a useful
therapeutic tool for inhibition of thrombin-induced VEGF
production in human neuroblastoma (NB-1) cells, and it
may be eﬀective in controlling disorders linked to thrombin-
induced VEGF production in neuronal cells [58].
Inhibitors of VEGF with diﬀerent speciﬁcities have been
evaluated in human neuroblastoma NGP-GFP xenografts in
nude mice [19]. These anti-VEGF agents are NX1838 (an
antihumanVEGF165 RNA-basedﬂuoropyrimidineaptamer),
monoclonal anti-human VEGF antibody, and VEGF-Trap
(a soluble composite decoy receptor consists of Ig-like
domains of VEGFR-1 and VEGFR-2). High-dose VEGF-
Trap showed the greatest inhibition of tumor growth leading
to regression of tumor vasculature in xenograft model of
neuroblastoma [19]. Combination of topotecan (a topoiso-
merase I inhibitor) with anti-VEGF antibody signiﬁcantly
suppressed tumor growth in neuroblastoma xenograft [59].
Continuous low-dose therapy with vinblastine and VEGFR-
2 antibody induces sustained tumor regression in neurob-
lastoma xenograft, diminishes tumor vascularity, and directs
inhibition of angiogenesis [60], suggesting that metronomic
therapy can inhibit endothelial cell proliferation, angiogene-
sis, and tumor growth.
4.1.2. Inhibition of Multiple Angiogenic-Related Factors.
VEGF, FGF-2, PDGF, SCF, and their cognate receptor
tyrosine kinases are strongly implicated in angiogenesis in
solid tumors like neuroblastoma. SU11657 (SUGEN) is a
selective multitargeted (class III/V) tyrosine kinase inhibitor
with anti-tumor and anti-angiogenic activity exerted by
targeting PDGFR, VEGFR, SCF receptor (c-Kit), and FMS-
related tyrosine kinase 3. Oral administration of SU11657
caused signiﬁcant inhibition of tumor growth as well as
of angiogenesis in SK-N-AS, N-Myc ampliﬁed IMR-32,
and SH-SY5Y human neuroblastoma xenografted athymic
nude mice. Immunohistochemical analysis revealed down
regulation of the expression of VEGFR-2, PDGFR-β,a n d
c-Kit suggesting that targeting of class III/V receptor tyro-
sine kinases and their ligands can suppress neuroblastoma
tumorigenicity and angiogenesis [23]. Imatinib mesylate,
a selective inhibitor of the tyrosine kinase c-Kit and
PDGFR, displayed concentration-dependent decreases in
cell viability, induction of apoptosis with ligand-stimulated
phosphorylation of c-Kit and PDGFR, and inhibition of
VEGF expression in 7 neuroblastoma cell lines. Oral ima-
tinib therapy showed anti-tumor eﬃcacy in xenografted
SCID mice [10]. SU6668, another receptor tyrosine kinase
inhibitor of VEGFR2, PDGFR, and FGFR1, in combination
withcyclophosphamidesigniﬁcantlyinhibitedVEGFR-2and
tumor growth in human neuroblastoma xenografts [37].
Therefore, therapy targeted to multiple angiogenic factors
appears to be a novel treatment modality in neuroblasto-
ma.
4.1.3. Retinoids for Inhibition of Angiogenesis in Neuroblas-
toma. Retinoids, a class of natural or synthetic compounds
structurally related to vitamin A, hold great promises for the
prevention and treatment of cancer. The cell diﬀerentiating8 Journal of Oncology
properties and anti-cancer activity of the retinoids all-trans
retinoic acid (ATRA) and 13-cis retinoic acid (13-CRA)
are well established in several in vitro and in vivo models
[61, 62]. Retinoids are signaling molecules that are involved
in proliferation, diﬀerentiation, and apoptosis both via non-
receptor and nuclear-receptor-mediated pathways thereby
altering gene expression. ATRA induces the expression of
both mRNA and protein of the diﬀerentiation marker
manganese superoxide dismutase (MnSOD) in human neu-
roblastoma (SK-N-SH) cells with involvement of NF-κB
and SOD2 genes, contributing to the concept of using
retinoids in cancer therapy [63]. Retinoic acid reduces
human neuroblastoma cell migration and invasiveness as
evident from down regulation of expression of doublecortin
(a microtubule-associated protein involved in neuronal
migration) and lissencephaly-1 (another protein involved
in neuronal migration) and upregulation of expression of
neuroﬁlament protein-68 in human neuroblastoma SK-N-
SH cell line [64]. Retinoic acid causes PI3K and PKC-
dependent upregulation of 2 putative α-secretases and the
disintegrin metalloproteinases ADAM10 and TACE, stim-
ulates α-secretase processing of amyloid precursor protein
(APP), and down regulates β-secretase cleavage thereby
leading to suppression of amyloid-β f o r m a t i o ni nh u m a n
neuroblastoma SH-SY5Y cells (Figure 3). The PI3K inhibitor
LY294002 and the PKC inhibitor bisindolylmaleimide XI
reduced the retinoid-mediated eﬀect on ADAM10 protein
levelsandcompletelyabolishedtheeﬀectonTACEindicating
involvement of PI3K- and PKC-mediated signaling pathway
in retinoic acid-induced upregulation of secretase [65].
Combined IFN-γ and retinoic acid treatment targets the N-
Myc/Max/Mad1 signaling pathway and represses expression
oftheN-Myc/Mad1targetgenesornithinedecarboxylaseand
hTERT, indicating that this combination strategy may have
therapeutic beneﬁts in targeting N-Myc function in high-
risk, N-Myc-ampliﬁed neuroblastoma patients [39]. Non-
genomic actions of retinoic acid on neuroblastoma SH-SY5Y
cells is mediated by the classical nuclear receptor, retinoic
acid receptor (RAR), resulting in activation of PI3K and
MAPK signaling pathways contributing to retinoic acid-
induced diﬀerentiation [66]. Combination of retinoic acid
with histone deacetylase inhibitors (HDACi) could result in
improved anti-tumorigenic activity. The HDACi trichostatin
A (TSA), sodium butyrate, and suberoylanilide hydroxamic
acid (SAHA) alone and in combination with retinoic acid
can increase cyclin kinase inhibitor (CKI) mRNA levels
in human neuroblastoma SH-SY5Y cells, and activate CKI
promoters to inhibit tumor cell growth in neuroblastoma
[67]. ATRA through involvement and activation of RAR
and ERK 1/2 induces COX-2 and prostaglandin E2 synthesis
in human neuroblastoma SH-SY5Y cells and this eﬀect is
completely abolished by the RAR pan-antagonist LE540 or
the MEK-1 inhibitor PD98059 suggesting involvement of
RAR and kinase-dependent mechanisms for ATRA-induced
COX-2 activity [68]( Figure 3). Genomic action of ATRA
includes caspase-8 transcription via CREB-phosphorylation
leading to apoptosis in neuroblastoma cells [69]. Retinoic
acid induces cell cycle arrest and diﬀerentiation through
degradation of the F-box protein Skp2 and stabilization of
the cyclin-dependent kinase inhibitor p27 (Figure 3). Skp2
is degraded by anaphase-promoting complex (APC) (Cdh1).
Retinoic acid downregulates Rae1 (a nuclear export factor),
facilitates APC- (Cdh1-) mediated Skp2 degradation leading
to the arrest of cell cycle progression and diﬀerentiation in
neuroblastoma SH-SY5Y cells [70]( Figure 3).
N-(4-hydroxyphenyl) retinamide (4-HPR), also known
as fenretinide, is a synthetic retinoid that induces anti-
proliferativeactivityandapoptosis,inhibitsangiogenesisand
cell motility, and decreases invasiveness in a wide variety
of human cancer cell lines and mammary, prostate, and
ovarian tumors in transgenic mice. 4-HPR can activate
retinoid receptor-dependent and independent pathways for
induction of apoptosis. 4-HPR induces the gene expression
of BBC3, pro-apoptotic member of the Bcl-2 family, to
trigger apoptosis in neuroblastoma cell lines [71]. 4-HPR
also potentiates NF-κBa c t i v i t y ,I κBα phosphorylation, pro-
duction of reactive oxygen species (ROS), 12-lipoxygenase
activity, and GADD153 transcription factor activity to elicit
apoptotic response in neuroblastoma SH-SY5Y cells [72]. 4-
HPR,IFN-γ,anddemethylatingagent5-aza-cytidineactivate
the promoter region of caspase-8 in neuroblastoma cells and
regulatebothconstitutiveandinduciblecaspase-8expression
in pathophysiological condition [73]. 4-HPR is also found
to upregulate ceramide level and metabolism of ceramide
to gangliosides via glucosylceramide synthase and GD3
synthase leading to activation of ROS signaling pathway via
12-LOX resulting in oxidative stress and neuroblastoma cell
deathbyinductionofthetranscription factorGADD153and
the Bcl-2-related Bak protein [74]. 4-HPR caused sustained
activation of JNK/p38 MAPK pathway and augmented
apoptosis in a ROS-dependent manner in neuroblastoma
cells [75]. 4-HPR through inhibition of both VEGF and
FGF-2inducedendothelialcellproliferationtodownregulate
angiogenesis in neuroblastoma [76]. Retinoid in combina-
tion with an anti-angiogenic factor may provide an eﬀective
treatment strategy for controlling neuroblastoma.
4.1.4. Anti-Angiogenic Inhibitors of Methionine Aminopep-
tidase. Theanti-angiogenicinhibitorsofmethionineamino-
peptidase (MetAP2) may hold a key role in therapeutic man-
agement of neuroblastoma. MetAP2 is a cytoplasmic enzyme
responsible for promoting endothelial cell proliferation,
migration, and induction of angiogenesis in neuroblastoma
[54]. The concentration of MetAP2 has been found to be
higher in neuroblastomas [37].
TNP-470, an irreversible inhibitor of MetAP2, showed
anti-angiogenic activity in preclinical models of neuroblas-
toma. TNP-470 as monotherapy or in combination with a
cytotoxic agent such as cisplatin, paclitaxel, or cyclophos-
phamide signiﬁcantly inhibited tumor angiogenesis [54].
TNP-470 signiﬁcantly inhibited growth rate and tumori-
genecity in several neuroblastoma xenografts [54, 77]. TNP-
470 treatment in small neuroblastoma tumors was found to
exhibitchromaﬃndiﬀerentiationandinductionofapoptosis
[54]. Microspheres containing TNP-470 strongly inhibit in
vivo hepatic metastasis of neuroblastoma [78]. However,
TNP-470 has a few limitations such as neurologic toxicities.Journal of Oncology 9
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Figure 3: Genomic and non-genomic actions of all-trans retinoic acid (ATRA). Genomic action of ATRA includes caspase-8 transcription,
cell cycle arrest, and apoptosis. Non-genomic action of ATRA involves induction of PI3K/Akt pathway for upregulation of secretase. ATRA
activates retinoic acid receptor (RAR) and MAPK signaling pathway for contribution to diﬀerentiation in neuroblastoma.
Another reversible inhibitor of MetAP2 is A-357300,
which is a promising therapeutic agent against neuroblas-
toma. A-357300 alone or in combination with cyclophos-
phamidesigniﬁcantlycausedtumorregressionandincreased
survival rate in CHP-134-derived neuroblastoma xenografts
without any toxicity [79]. A-357300 induces cell cycle
arrest G1 phase in neuroblastoma cells, and showed anti-
angiogenic and anti-tumor potential in neuroblastoma
murinemodels[80].A800141,anotherorallyactiveinhibitor
of MetAP2, showed potent anti-angiogenic and anti-tumor
activities in several tumor xenografts including neuroblas-
toma, B-cell lymphoma, and colon and prostrate carcinomas
[81].
4.1.5. Endostatin for Inhibition of Angiogenesis in Neuroblas-
toma. Endostatinisa20kDafragmentofcollagenXVIIIthat
acts as an endogenous inhibitor of endothelial cell prolifera-
tion, tumor angiogenesis, and tumor growth. Recombinant
human endostatin (rhEndostatin) worked as potent anti-
angiogenic agent and was eﬀective against human neu-
roblastoma xenograft model [82]. In another gene therapy
approach, the angiogenesis inhibitor endostatin and the
potent immunogen green ﬂuorescent protein (GFP) were
delivered to murine neuroblastoma cells prior to inoculation
of tumor cells into syngeneic immunocompetent mice [54].
The combination of endostatin and GFP showed synergistic
anti-tumor and immunogenic response suggesting that both
anti-angiogenic and immunotherapeutic strategies worked
to control neuroblastoma. Also, pre-existing primary neu-
roblastoma xenografts could hold back the growth of a new
secondary subcutaneous tumor, inhibit angiogenesis, and
induce apoptosis due to release of endostatin from the tumor
[83].
4.1.6. Targeting HGF/c-Met for Inhibition of Angiogenesis in
Neuroblastoma. One promising strategy to inhibit angio-
genesis in neuroblastoma is to target the signaling pathway
of HGF (also known as scatter factor, SF) along with its
receptor HGFR (also known as c-Met) that plays important
roles in mitogenic, motogenic, and morphogenic regulation
of angiogenesis, tumor growth, and metastasis. Inhibitors
of this signaling pathway have been shown to inhibit
angiogenesis in multiple in vitro and in vivo models of
cancers and may be used as an eﬀective therapy to treat
cancers. HGF and c-Met are upregulated in many human
cancersincludingneuroblastoma[84]andhighlyresponsible
for neuroblastoma invasion in vitro and in vivo. Therefore,
inhibitors targeting HGF/c-Met signaling may be an eﬀective
therapeutic approach to control angiogenesis and prevent
tumor growth. The ﬁrst strategy for inhibition may be
blocking the binding of HGF to c-Met with the use of
HGF antagonists and antibodies against HGF/c-Met. The
HGF/c-Met antagonists NK4, uncleaved HGF, Sema, decoy
Met, and recombinant variant Met were used previously.
The antibodies targeting HGF are L2G7 (Galaxy Biotech),
AMG102 (Amgen), OA-5D5 (Genentech), and CE-3556221
(Pﬁzer) that can inhibit tumor angiogenesis by blocking10 Journal of Oncology
the binding of HGF/c-Met [52]. In another study, it has
been reported that inhibition of HGF activity by anti-HGF-
antibodies or suppressing the function of c-Met by siRNA
can repress the TrkB-induced invasiveness [51].
Next strategy is to inhibit the HGF/c-Met signaling
pathway (a) by targeting Tyr kinase domain of c-Met for
inhibiting tyrosine phosphorylation with inhibitors such as
SU11274, PF2341066 (Pﬁzer), XL880, and XL184 (Exelixis)
and (b) by targeting inhibitors of downstream eﬀectors
of HGF/c-Met signaling such as PI3K inhibitor LY294002
(to inhibit HGF/c-Met-induced cell motility) and MEK
inhibitor PD98059 (to inhibit HGF/c-Met-mediated cell
invasion). The other important inhibitors are Src inhibitor
PD180970 and SU6656 that inhibit HGF/c-Met-induced
Src and STAT3 activity [52]. Another inhibitor PHA665752
has been reported to suppress c-Met activity and block
HGF-induced cell migration and proliferation of c-Met-
positive neuroblastoma cells [85]. Thus, targeting HGF/c-
Met signaling pathways could be a beneﬁcial approach for
controlling angiogenesis in neuroblastoma.
4.2. Combination Anti-Angiogenic Therapy to Treat Neurob-
lastoma. Despite multimodal myeloablative chemotherapy,
thispediatricmalignancyhasapoorprognosis.Currentther-
apeutic strategies including combination of novel targeted
drugs such as signal transduction and angiogenesis inhibitor,
diﬀerentiation and apoptosis inducers, and immunothera-
peutic modulators can provide superior management and
prevention of neuroblastoma. Combination of trichostatin
A (TSA) and interferon-alpha (IFN-α) showed the most
potent anti-angiogenic therapeutic strategy for devastating
neuroblastoma [86]. Combination of TSA and IFN-α not
only decreased endothelial cell migration, invasion, and
capillary tubule formation but also inhibited expression
of VEGF, HIF-1α,a n dM M P - 9i nn e u r o b l a s t o m ac e l l s
[86]. Sunitinib (targeted against PDGFR and VEGFR) and
rapamycin showed synergistic inhibition of tumor growth,
angiogenesis, and anti-metastatic activity in both neurob-
lastoma cell culture and xenograft models suggesting the
anti-cancer eﬃcacy of this combination therapy [87]. The
anti-VEGF antibody bevacizumab treatment in orthotopic
neuroblastoma xenograft model causes normalization of
the tumor vasculature due to VEGF blockade resulting in
improved delivery and anti-tumor eﬃcacy of chemotherapy
[88]. Combination of the thrombospondin-1 peptide ABT-
510 with valproic acid was highly eﬀective to regress tumor
growth and microvascular density in two diﬀerent N-
Myc-ampliﬁed cell lines-derived neuroblastoma xenografts
when compared with monotherapy suggesting the potency
of combination anti-angiogenic therapy for treatment of
neuroblastoma[89].Bortezomib(proteasomeinhibitor)and
4-HPR showed synergistic anti-tumor and anti-angiogenic
activities in neuroblastoma cell culture and xenograft mod-
els through involvement of endoplasmic reticulum stress
response [90]. Anti-angiogenic agents (arginine deiminase,
SU5416, and DC101) in combination with simultaneous
irradiation inhibited in vivo growth of neuroblastomas with
subsequent reduction in number of tumor vessels [91].
Valproic acid in combination with INF-α synergistically
inhibited growth of malignant phenotype of human N-Myc-
ampliﬁed neuroblastoma BE(2)-C cells [92]. This combi-
nation therapy caused marked downregulation of N-Myc,
Bcl-2, and neural cell adhesion molecule with induction of
diﬀerentiation in neuroblastoma [92].
4.3. Gene Therapy and Immunotherapy for Inhibition of
Angiogenesis in Neuroblastoma. In gene therapy approach,
genetic material encoding the therapeutic protein is trans-
ferred into the mammalian cells. Viral vector-mediated gene
delivery of angiogenic inhibitors shows potent therapeutic
promises against malignant neuroblastoma. Construction of
retroviral and adenoviral vectors expressing the angiogenic
inhibitor proteins is being tested in diﬀerent neuroblastoma
murine tumor models. In this approach, host cells are
engineered to make the anti-angiogenic protein in vivo on
long-termbasiswithoutdailyadministrationofrecombinant
proteins. Single vector through the delivery of multiple
genes can therefore target several angiogenic pathways. Gene
therapy by retroviral vector for cell-mediated in vivo delivery
of TIMP-3 could suppress tumor-induced angiogenesis and
tumor growth [93]. Two replication-defective retroviral
vectors were used to transduce murine neuroblastoma cells
(NXS2). Single GFP expression was ineﬀective to reduce
tumor growth whereas engineered expression of Flk-1
resulted in inhibition of endothelial cell proliferation and
migration and also restriction of neuroblastoma growth
[94]. Adeno-associated virus- (AAV-) mediated delivery of
IFN-β with subsequent administration of TSA in vitro and
in vivo in murine model of retroperitoneal neuroblastoma
was highly eﬀective, showing reduction in tumor cell count
with elevated expression of p21 suggesting the potential
of this therapy to treat this devastating disease [95]. AAV-
mediated systemic delivery of human IFN-β (AAV-hIFN-β)
in combination with low-dose cyclophosphamide showed
anti-angiogenic activity with down regulation of VEGF
and FGF-2 and also caused complete tumor regression
in orthotopic retroperitoneal and disseminated models of
neuroblastoma [95]. Triple combination of conditionally
replicating oncolytic herpes simplex virus-1 vectors armed
with IL-12, IL-18, or soluble B7-1 potentiated in vivo anti-
tumor eﬃcacy by augmenting T-cell-mediated response in
neuroblastoma Neuro2a model [96]. Thus, insertion of
immunostimulatory transgenes into viral genome could be
a useful strategy for neuroblastoma therapy [96]. Neurob-
lastoma immunotherapy using cytokines may have direct
anti-tumorandimmunomodulatoryeﬀects.Co-transfection
of IL-2 and IL-12 in Neuro2a cells down regulated in vivo
tumorigenicity and provided CD4+ T cell and CD8+ T cell
mediatedimmunotherapeuticresponsesinsyngenicneurob-
lastoma model [97]. Immunogene therapy with IL-12- and
IL-15-engineered neuroblastoma Neuro2a cells showed ther-
apeutic eﬃcacy by enhancement of CD8+ T-cell immunore-
sponses and potentiated the survivability of neuroblastoma-
bearing syngenic mice [98]. Inhibition of angiogenesis by
targeted immunotherapy may provide a novel treatment
modalityagainstneuroblastoma.Anti-angiogenicintegrinαv
antagonist and antibody-IL-2 fusion protein induced tumorJournal of Oncology 11
regression and dramatically decreased tumor vessel density
in syngenic neuroblastoma model [99].
4.4. Vascular Targeting for Inhibition of Angiogenesis in
Neuroblastoma. Vascular targeting has tremendous potential
in neuroblastoma therapy. Vascular targeting with selective
occlusion of pre-existing tumor blood vessels can induce
tumor suppression by destruction of tumor vasculature
and extensive necrosis. Two types of vascular targeting
agents, small molecules (e.g., microtubule destabilizing
agents, ﬂavonoids), and ligand-based fusion proteins (e.g.,
immunotoxins, liposomally encapsulated drugs, antibodies
conjugated with cytokines, and gene therapy) hold key role
in tumor regression. Sterically stabilized immunoliposomal
(SIL)therapybytargeteddeliveryofentrappeddrugstosolid
tumors can potentiate therapeutic eﬃcacy. SIL loaded with
doxorubicin (DXR) and targeted to the disialoganglioside
receptor GD-2 in human neuroblastoma model can cause
marked tumor regression. In neuroblastoma xenografts, the
combined delivery of NGR peptide (targeting angiogenic
endothelialcellmarkeraminopeptidaseN)withDXR-loaded
liposome showed dramatic tumor suppression by destruc-
tion of tumor vasculature [100]. Tumor vascular targeting
by TNF-α with chemotherapeutic drug GNGRG peptide
or coupling this peptide to the surface of liposomal DXR
could augment the penetration of chemotherapeutic drugs
in subcutaneous tumor models and therefore serve as a novel
treatment strategy for neuroblastoma [101]. Immunotoxins-
and antibody-based therapy showed promises in eradication
ofsolidtumors.Cytokinegenetransfectionoftumorcellsfor
induction of expression of major histocompatibility complex
(MHC) class II in tumor endothelium was carried out in a
neuroblastoma murine model [102]. The delivery of anti-
class II-deglycosylated Ricin A chain caused destruction
of IFN-γ-activated endothelial cells in vitro and complete
thrombosis and decay of vasculature of neuroblastoma
tumors in vivo suggesting that immunoconjugates attached
with antibodies against tumor endothelium could oﬀer
extensive therapy to numerous solid tumors in humans
[102].
5. Conclusion and FutureDirection
Despite multimodal therapeutic approaches, the mortality
rate is very high in patients with malignant neuroblastoma.
Noveltreatmentstrategiesforimprovingpatientsurvivaland
decreasing therapy-related toxicity are urgently warranted.
Angiogenesis appears to be a primary requirement for
growth, invasion, and metasatsis of malignant neuroblas-
tomas. Inhibition of neovascularization by anti-angiogenic
agent could provide promising therapeutic approach for
treatment of neuroblastoma. Synergistic treatment modal-
ities with the use of anti-angiogenic drugs in combination
chemotherapy [103] and newer targeted therapy for inhibit-
ing vascular sprouting and tumor vasculogenesis could
provide eﬀective tools for future therapies for this type
of deadly cancer. Continuous low-dose chemotherapy or
“metronomic dosing” could potentiate anti-angiogenic and
apoptotic eﬀects of cytotoxic agents on both proliferating
endothelial cells and tumor cells. Metronomic scheduling
of imatinib with the chemotherapeutic drug DXR showed
anti-proliferative activity and apoptosis induction in both
neuroblastoma cell lines and xenograft model [104]. Inte-
grated treatment strategies for inducing tumor cell death,
diﬀerentiation, and apoptosis, overcoming multiple drug
resistance, and inhibiting angiogenesis with preclinical eval-
uation should provide justiﬁcation for their future selection
as clinical trials in high-risk neuroblastoma.
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